12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Duvoglustat: Preliminary Phase II data

Preliminary data from 16 patients with Pompe's disease in the first 3 cohorts of the open-label, international Phase II Study 010 trial showed that single ascending-doses of oral AT2220 plus enzyme replacement therapy (ERT) with Myozyme/ Lumizyme alglucosidase alfa produced dose-dependent increases in recombinant human GAA activity in plasma samples in all patients. Compared to Myozyme/Lumizyme alone, mean fold-increases in recombinant human GAA activity as measured by plasma area...

Read the full 338 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >